Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma

ABSTRACT: Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma

PROVIDER: PRJNA790925 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma

Project description:We studied 20 candidate genes (HCC hub genes, potential drug target genes, predominant somatic mutant genes) retrieved from available literature and public databases with potential to be used as biomarkers for the prognosis of HCC and prediction of treatment outcome. We analysed expression of the genes by RT-qPCR in 30 HCC tumor and adjacent non-tumor paired samples from Vietnamese patients.

2021-12-25 | GSE191298 | GEO

Molecular characterization of Georgia cohort of primary breast cancer FFPE tissues on custom breast cancer DASL panel

2009-10-23 | GSE18539 | GEO

Human buffy coat gene expression, custom 250-plex Nanostring panel

Project description:Buffy coat PBMC RNA expression was tested using a custom Nanostring probe panel, to identify general immune and glucocorticoid receptor-associated immune genes. ClinicalTrials.gov Identifier: NCT00824941

2019-11-01 | GSE124549 | GEO

Targeted RNASeq using a custom panel of metabolic genes

Project description:Targeted RNASeq using a custom panel of metabolic genes

| PRJNA605015 | ENA

Molecular characterization of Georgia cohort of primary breast cancer FFPE tissues on custom breast cancer DASL panel

Project description:Analysis of 143 formalin-fixed, paraffin-embedded (FFPE) primary breast tumors using a Custom Breast Cancer Panel and Human Cancer Panel for the DASL platform. Molecular markers between the pathology defined subtypes of breast cancer were assessed to hypothesize potential therapeutic targets specific to the subtypes Molecular Characterization of 143 primary breast carcinomas including 101 triple negative (TN: ER-, PR-, HER2-), 3 HER2-positive (HER2+: ER-, PR-, HER2+), and 39 hormone receptor-positive (HR+: ER+ and/or PR+)

2009-10-23 | E-GEOD-18539 | biostudies-arrayexpress

Human buffy coat gene expression, custom 250-plex Nanostring panel

Project description:Human buffy coat gene expression, custom 250-plex Nanostring panel

| PRJNA512473 | ENA

Evaluation of ATAD2 as a potential target in hepatocellular carcinoma

Project description:We evaluated differentially expressed genes (DEGs) between hepatocellular carcinoma cell lines (Hep3B, SNU449, and PLC/PRF/5) treated with ATAD2 siRNA or control using Affymetrix array data whether ATAD2 could be potential target in hepatocellular carcinoma.

2022-06-15 | GSE178243 | GEO

Targeted RNASeq using a custom panel of metabolic genes

Project description:Purpose: The purpose of this experiment was to determine the time point following activation at which greatest transcriptional differences in metabolic genes were observed between primary human CD4+ T cells treated with metformin + 2-deoxyglucose combination regimen and cells treated with vehicle. Methods: Targeted RNA-Seq data was generated from primary human CD4+ T cell mRNA using a Qiagen custom designed panel of metabolic genes and the Illumina TruSeq stranded mRNA prep. Results: We obtained differential gene expression between metformin + 2-deoxyglucose and vehicle-treated cells using the DESeq2 app in Illumina Basespace for a set of metabolic genes during different time points following activation, and found the greatest changes at 24hr.

2020-06-15 | GSE144352 | GEO

Molecular characterization of Quebec Cohort of Primary Breast Cancer FFPE Tissues on the Human Cancer Panel

Project description:Analysis of 97 formalin-fixed, paraffin-embedded (FFPE) primary breast tumors using Illumina DASL microarray technology on a Custom Breast Cancer Panel and the Illumina Human Cancer Panel. Molecular markers between the pathology defined subtypes of breast cancer were assessed to hypothesize potential therapeutic targets specific to the subtypes

2009-10-23 | GSE17650 | GEO

A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus

Project description:Background: The identification of new high sensitivity and specificity markers for HCC are essential. We aimed to identify serum microRNAs for diagnosing hepatitis B virus (HBV) â??related HCC. Methods: Serum microRNA expression was investigated with four cohorts including 667 participants (261 HCC patients ,233 cirrhosi patients and 173 healthy controls), recruited between August 2010 and June 2013. First, An initial screening of miRNA expression by Illumina sequencing was performed using serum samples pooled from HCC patients and controls,respectively. Quantitative reverse-transcriptase polymerase chain reaction assay was then applied to evaluate the expression of selected microRNAs. A logistic regression model was constructed using a training cohort (n=357) and then validated using a cohort(n=241). The area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy. Results: , We identified 8 miRNAs(hsa-miR-206, hsa-miR-141-3p, hsa-miR-433-3p, hsa-miR-1228-5p, hsa-miR-199a-5p, hsa-miR-122-5p, hsa-miR-192-5p and hsa-miR-26a-5p.) formed a miRNA panel that provided a high diagnostic accuracy of HCC (AUC=0.887 and 0.879 for training and validation data set, respectively). The microRNA panel can also differentiate HCC from healthy (AUC =0.894) and cirrhosis (AUC = 0.892), respectively. Conclusions:We found a serum microRNAs panel that has considerable clinical value in diagnosing HCC. 9 serum samples pooled from 3 healthy control donors and 3 HCC patients, 3 cirrhosi patients treated at The First Affiliated Hospital of Soochow University were subjected to Illumina HiSeq 2000 deep sequencing to identify the miRNAs that were significantly differentially expressed.

2015-12-20 | E-GEOD-59418 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data